PH12012500504A1 - N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer - Google Patents
N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancerInfo
- Publication number
- PH12012500504A1 PH12012500504A1 PH1/2012/500504A PH12012500504A PH12012500504A1 PH 12012500504 A1 PH12012500504 A1 PH 12012500504A1 PH 12012500504 A PH12012500504 A PH 12012500504A PH 12012500504 A1 PH12012500504 A1 PH 12012500504A1
- Authority
- PH
- Philippines
- Prior art keywords
- cancer
- phthalazinamine
- pyridinyl
- pyrimidinyl
- thienyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000003080 antimitotic agent Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- IVUGFMLRJOCGAS-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine Chemical compound CC1=CSC(C=2C3=CC=CC=C3C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=C1 IVUGFMLRJOCGAS-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003989 Aurora kinases Human genes 0.000 abstract 1
- 108090000433 Aurora kinases Proteins 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152709P | 2009-09-11 | 2009-09-11 | |
| PCT/US2010/048247 WO2011031842A1 (en) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012500504A1 true PH12012500504A1 (en) | 2015-04-29 |
Family
ID=43216900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/500504A PH12012500504A1 (en) | 2009-09-11 | 2010-09-09 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20120028917A1 (https=) |
| EP (2) | EP2475368B1 (https=) |
| JP (1) | JP5851403B2 (https=) |
| KR (1) | KR20120082896A (https=) |
| CN (1) | CN102869361A (https=) |
| AU (1) | AU2010292225C1 (https=) |
| BR (1) | BR112012008325A2 (https=) |
| CA (1) | CA2773838C (https=) |
| CL (1) | CL2012000640A1 (https=) |
| CR (1) | CR20120171A (https=) |
| DK (1) | DK2475368T3 (https=) |
| EA (1) | EA020526B1 (https=) |
| ES (1) | ES2528485T3 (https=) |
| HK (1) | HK1205457A1 (https=) |
| HR (1) | HRP20150104T1 (https=) |
| HU (1) | HUE024568T2 (https=) |
| IL (1) | IL218569A0 (https=) |
| MA (1) | MA33658B1 (https=) |
| ME (1) | ME02048B (https=) |
| MX (1) | MX2012003041A (https=) |
| NZ (1) | NZ598758A (https=) |
| PE (1) | PE20120895A1 (https=) |
| PH (1) | PH12012500504A1 (https=) |
| PL (1) | PL2475368T3 (https=) |
| PT (1) | PT2475368E (https=) |
| RS (1) | RS53807B1 (https=) |
| SG (1) | SG179102A1 (https=) |
| SI (1) | SI2475368T1 (https=) |
| SM (1) | SMT201500028B (https=) |
| TN (1) | TN2012000110A1 (https=) |
| TW (1) | TW201121956A (https=) |
| UA (1) | UA107675C2 (https=) |
| WO (1) | WO2011031842A1 (https=) |
| ZA (1) | ZA201202472B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015518053A (ja) * | 2012-05-31 | 2015-06-25 | アムジエン・インコーポレーテツド | 癌の治療のためのａｍｇ９００の使用 |
| CN103664737A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| US9963701B2 (en) | 2013-09-30 | 2018-05-08 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor |
| HRP20220718T1 (hr) | 2013-11-11 | 2022-09-30 | Amgen Inc. | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka |
| US10053452B2 (en) | 2013-12-03 | 2018-08-21 | Amgen Inc. | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof |
| SG11201606869TA (en) * | 2014-02-21 | 2016-09-29 | Frost Biolog Inc | Antimitotic amides for the treatment of cancer and proliferative disorders |
| CN109313197A (zh) * | 2016-04-15 | 2019-02-05 | 费利克斯疗法公司 | 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合 |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES3060664T3 (en) | 2018-06-12 | 2026-03-27 | Amgen Inc | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060178318A1 (en) * | 2003-07-03 | 2006-08-10 | Shubha Anand | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| AU2007208351C1 (en) * | 2006-01-23 | 2011-07-07 | Amgen Inc. | Aurora kinase modulators and method of use |
| UA93538C2 (en) * | 2006-01-23 | 2011-02-25 | Амген Инк. | Aurora kinase modulators and method of use |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
-
2010
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-09 PH PH1/2012/500504A patent/PH12012500504A1/en unknown
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en not_active Ceased
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 RS RS20150065A patent/RS53807B1/sr unknown
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Ceased
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
-
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
-
2013
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/en unknown
-
2015
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500504A1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| WO2008089388A3 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
| MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| PL1951729T3 (pl) | Pochodne pirymidyny połączone przez atom tlenu | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
| SG178873A1 (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| MX2009009537A (es) | Nanoparticula que comprende rapamicina y albumina como agente anticancer. | |
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
| MX2009008073A (es) | Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. | |
| PL1732926T3 (pl) | Inhibitory kinezyn motorycznych | |
| WO2011094260A3 (en) | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | |
| MX2008016520A (es) | Medicamentos. | |
| WO2009038771A3 (en) | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers | |
| CY1115851T1 (el) | Ν-4(-((3-(2-αμινο-4 πυριμιδινυλ)-2-πυριδινυλ)οξυ)φαινυλ)-4-(4-μεθυλ-2-θειενυλ)-1-φθαλαζιναμινη για χρηση στη θεραπεια ανθεκτικου σε αντιμιτωτικο παραγοντα καρκινου | |
| UA101610C2 (ru) | Наночастица, которая содержит рапамицин и альбумин, в качестве противоракового агента | |
| MY140324A (en) | Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer | |
| MY148385A (en) | Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |